Company Overview and News
KUALA LUMPUR, Oct 3 — Investigations conducted by Lingkaran Trans Kota Holdings Bhd (Litrak) found that flash floods which occurred at the Bandar Puteri intersection in Puchong near here yesterday were caused by mudslides which flowed onto the Damansara-Puchong Expressway (LDP) and heavier-than-normal rain.
KUALA LUMPUR (Oct 2): Investigations conducted by Lingkaran Trans Kota Holdings Bhd (LITRAK) found that flash floods which occurred at the Bandar Puteri intersection in Puchong near here today were caused by mudslides which flowed onto the Damansara-Puchong Expressway (LDP) and heavier-than-normal rain.
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF
TOLL concessionaires were granted a reprieve early last week when Works Minister Baru Bian announced that the scrapping of tolls nationwide would be deferred until fiscal conditions permit.
5932 6645 7078
KUALA LUMPUR (Aug 14): The FBM KLCI struggled to recoup some lost ground in the morning session today amid some choppy trading.
7047 BATS 4162 5246 5202 9334 6033 7233 2852 5029 PNADF 5347 5225 7668 6645 TNABY TNABF Q0F IHHHF PNAGF
KUALA LUMPUR (Aug 14): Lingkaran Trans Kota Holdings Bhd (Litrak) shares jumped 29% this morning following news that the government has agreed to defer toll abolishment until the country's fiscal position improves.
KUALA LUMPUR (Aug 14): The FBM KLCI reversed its earlier losses and clawed into positive territory at mid-morning today, lifted by select blue chips including Tenaga Nasional Bhd.
APEXF 7090 8621 5681 7248 6033 2593 7079 PNADF 5347 5225 8613 6645 TNABY TNABF Q0F IHHHF PNAGF
KUALA LUMPUR: Lingkaran Trans Kota Holdings Bhd (Litrak) surged 30% in early trade Tuesday on news that toll abolishment will need to be postponed until the country’s economic condition is stable.
KUALA LUMPUR: Gamuda Bhd, the biggest shareholder of Syarikat Pengeluar Air Sungai Selangor Sdn Bhd (SPLASH), is said to be keen on accepting the Selangor state’s offer to buy out SPLASH’s water treatment assets at RM2.55 billion, although the price tag is slightly lower than one time their book value — the ideal valuation that it has wanted, according to industry sources.
KUALA LUMPUR (Aug 3): The FBM KLCI clawed into positive territory at the midday break today, lifted by gains at Tenaga Nasional Bhd and other select blue chips.
HLFBF 7172 2089 5014 0020 2852 KLKBY 5347 3867 TNABY MYTEF PNAGF UPBMF 1082 7765 6033 5139 2445 PNADF 4863 6645 0900 5819 MYPRY TNABF
KUALA LUMPUR (July 18): The FBM KLCI pared down its earlier losses substantially at mid-morning today, tracking the advance at key Asian markets.
7172 PBLOF 7053 8133 7087 1295 7153 7123 7079 0176 4588 3026 6645 5819
KUALA LUMPUR (June 12): The FBM KLCI remained under pressure at mid-morning today, dragged by select index-linked blue chips.
HLFBF 7251 UPBMF 1082 7113 5032 TPGVF BATS 4162 7153 5168 2089 9334 TGLVY 5139 0047 5347 3026 0104 0900 6645 TNABY TNABF HRGHY
ONE of the giants of the local construction industry, Gamuda Bhd has been involved in infrastructure developments in the country over the past two decades or so — after the likes of United Engineers Bhd were laid low by the Asian financial crisis of the late 1990s.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...